NovoCure (NVCR) Other Operating Expenses (2014 - 2026)

NovoCure has disclosed Other Operating Expenses across 13 years of filings, most recently posting $58.4 million for Q1 2026.

• Other Operating Expenses for Q1 2026 came in at $58.4 million, up 4.6% year-over-year; the trailing twelve-month figure through Mar 2026 was $242.6 million (up 1.24% YoY), and the FY2025 annual result was $240.1 million, changed 0.42% from the prior year.
• Other Operating Expenses came in at $58.4 million for Q1 2026 at NovoCure, down from $68.7 million in the prior quarter.
• In the past five years, Other Operating Expenses ranged from a high of $68.7 million in Q4 2025 to a low of $37.9 million in Q1 2022.
• The 5-year median for Other Operating Expenses is $57.1 million (2025), against an average of $55.2 million.
• Across the five-year window, Other Operating Expenses soared 40.03% in 2023 and dropped 3.2% in 2024, its largest moves.
• NovoCure's Other Operating Expenses stood at $49.6 million in 2022, then rose by 19.26% to $59.2 million in 2023, then advanced by 13.89% to $67.4 million in 2024, then climbed by 1.85% to $68.7 million in 2025, then declined by 15.01% to $58.4 million in 2026.
• The last three Other Operating Expenses figures came in at $58.4 million (Q1 2026), $68.7 million (Q4 2025), and $58.5 million (Q3 2025), per Business Quant data.